Cellectis
Cellectis is a biotechnology company specializing in the development of gene editing technologies. Founded in 1999, Cellectis is headquartered in Paris, France, with additional offices in the United States. The company is known for its pioneering work in the field of genome engineering, particularly using TALEN and CRISPR technologies.
History[edit | edit source]
Cellectis was founded by Dr. André Choulika, a prominent figure in the field of genome editing. The company initially focused on the development of meganucleases for gene editing. Over the years, Cellectis expanded its technology portfolio to include TALEN and CRISPR systems, which have become the cornerstone of its research and development efforts.
Technology[edit | edit source]
Cellectis utilizes several advanced gene-editing technologies:
- Meganucleases: These are endonucleases that recognize and cut specific DNA sequences, allowing for precise gene editing.
- TALEN: Transcription Activator-Like Effector Nucleases are engineered proteins that can be designed to target specific DNA sequences for editing.
- CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats is a revolutionary gene-editing technology that allows for highly specific and efficient modification of DNA.
Applications[edit | edit source]
Cellectis' technologies have a wide range of applications, including:
- Immunotherapy: Developing CAR-T cell therapy for the treatment of various cancers.
- Agriculture: Enhancing crop traits such as yield, disease resistance, and stress tolerance.
- Gene therapy: Treating genetic disorders by correcting defective genes.
Collaborations and Partnerships[edit | edit source]
Cellectis has established numerous collaborations and partnerships with leading pharmaceutical and biotechnology companies. These partnerships aim to leverage Cellectis' gene-editing technologies for the development of novel therapies and products.
Research and Development[edit | edit source]
Cellectis is actively involved in research and development to advance its gene-editing platforms. The company has several ongoing clinical trials to evaluate the safety and efficacy of its CAR-T cell therapies in treating various types of cancer.
See also[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
